Literature DB >> 36083966

Inferring the initiation and development of myeloproliferative neoplasms.

Gurvan Hermange1, Alicia Rakotonirainy1, Mahmoud Bentriou1, Amandine Tisserand2,3,4, Mira El-Khoury2,3,4, François Girodon5,6, Christophe Marzac2,3,7,8, William Vainchenker2,3,7, Isabelle Plo2,3,7, Paul-Henry Cournède1.   

Abstract

The developmental history of blood cancer begins with mutation acquisition and the resulting malignant clone expansion. The two most prevalent driver mutations found in myeloproliferative neoplasms-JAK2V617F and CALRm-occur in hematopoietic stem cells, which are highly complex to observe in vivo. To circumvent this difficulty, we propose a method relying on mathematical modeling and statistical inference to determine disease initiation and dynamics. Our findings suggest that CALRm mutations tend to occur later in life than JAK2V617F. Our results confirm the higher proliferative advantage of the CALRm malignant clone compared to JAK2V617F. Furthermore, we illustrate how mathematical modeling and Bayesian inference can be used for setting up early screening strategies.

Entities:  

Keywords:  JAK2/CALR mutations; approximate bayesian computation; cancer early detection; mathematical modeling of cell populations; myeloproliferative neoplasms

Mesh:

Substances:

Year:  2022        PMID: 36083966      PMCID: PMC9478641          DOI: 10.1073/pnas.2120374119

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  32 in total

1.  The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.

Authors:  Sabrina Dupont; Aline Massé; Chloé James; Irène Teyssandier; Yann Lécluse; Frédéric Larbret; Valérie Ugo; Patrick Saulnier; Serge Koscielny; Jean Pierre Le Couédic; Nicole Casadevall; William Vainchenker; François Delhommeau
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

2.  Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.

Authors:  Ayalew Tefferi; Emnet A Wassie; Paola Guglielmelli; Naseema Gangat; Alem A Belachew; Terra L Lasho; Christy Finke; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani; Alexandra P Wolanskyj; Margherita Maffioli; Rosario Casalone; Annalisa Pacilli; Alessandro M Vannucchi; Francesco Passamonti
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

3.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

4.  To portray clonal evolution in blood cancer, count your stem cells.

Authors:  Anne-Marie Lyne; Lucie Laplane; Leïla Perié
Journal:  Blood       Date:  2021-04-08       Impact factor: 22.113

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

7.  The evolutionary dynamics and fitness landscape of clonal hematopoiesis.

Authors:  Caroline J Watson; A L Papula; Gladys Y P Poon; Wing H Wong; Andrew L Young; Todd E Druley; Daniel S Fisher; Jamie R Blundell
Journal:  Science       Date:  2020-03-27       Impact factor: 47.728

8.  Life histories of myeloproliferative neoplasms inferred from phylogenies.

Authors:  Nicholas Williams; Joe Lee; Emily Mitchell; Luiza Moore; E Joanna Baxter; James Hewinson; Kevin J Dawson; Andrew Menzies; Anna L Godfrey; Anthony R Green; Peter J Campbell; Jyoti Nangalia
Journal:  Nature       Date:  2022-01-20       Impact factor: 69.504

9.  Aging alters the epigenetic asymmetry of HSC division.

Authors:  M Carolina Florian; Markus Klose; Mehmet Sacma; Jelena Jablanovic; Luke Knudson; Kalpana J Nattamai; Gina Marka; Angelika Vollmer; Karin Soller; Vadim Sakk; Nina Cabezas-Wallscheid; Yi Zheng; Medhanie A Mulaw; Ingmar Glauche; Hartmut Geiger
Journal:  PLoS Biol       Date:  2018-09-20       Impact factor: 8.029

10.  Population dynamics of normal human blood inferred from somatic mutations.

Authors:  Henry Lee-Six; Nina Friesgaard Øbro; Mairi S Shepherd; Sebastian Grossmann; Kevin Dawson; Miriam Belmonte; Robert J Osborne; Brian J P Huntly; Inigo Martincorena; Elizabeth Anderson; Laura O'Neill; Michael R Stratton; Elisa Laurenti; Anthony R Green; David G Kent; Peter J Campbell
Journal:  Nature       Date:  2018-09-05       Impact factor: 49.962

View more
  1 in total

1.  Inferring the initiation and development of myeloproliferative neoplasms.

Authors:  Gurvan Hermange; Alicia Rakotonirainy; Mahmoud Bentriou; Amandine Tisserand; Mira El-Khoury; François Girodon; Christophe Marzac; William Vainchenker; Isabelle Plo; Paul-Henry Cournède
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-09       Impact factor: 12.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.